NASDAQ · CTMX
CytomX Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for CTMX: Nov 05, 2026
CytomX Therapeutics, Inc. Common Stock is expected to report earnings on 11/05/2026 after market close. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 3 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.09. The reported EPS for the same quarter last year was $-0.09.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.09 | $-0.08 | $-0.11 | 3 |
| Dec 2026 | $-0.10 | $-0.09 | $-0.12 | 3 |
| Mar 2027 | $-0.11 | $-0.08 | $-0.13 | 3 |
| Jun 2027 | $-0.12 | $-0.08 | $-0.15 | 3 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · MarketBeat · Zacks · NASDAQ.com- RTTNews · Aug 27, 10:38 AM EDTCytomX Secures FDA Fast Track For Varseta-M In Metastatic Colorectal Cancer(RTTNews) – CytomX Therapeutics, Inc. (CTMX) announced that the U.S. FDA has granted Fast Track Designation to its lead candidate Varsetatug masetecan (Varseta-M) for patients with relapsed/refractory metastatic colorectal cancer.
- MarketBeat · Aug 6, 9:03 PM EDTCytomX Therapeutics Q2 Earnings Call HighlightsCytomX Therapeutics (NASDAQ:CTMX) said its second-quarter focus remained on advancing Varseta-M, an EpCAM-targeting antibody-drug conjugate being developed for metastatic colorectal cancer, while expanding the program into combination regimens and additional gastrointestinal canc
- Zacks · Aug 6, 7:10 PM EDTCytomX Therapeutics (CTMX) Reports Q2 Loss, Lags Revenue EstimatesCytomX Therapeutics (CTMX) delivered earnings and revenue surprises of +18.18% and -80.21%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Jul 8, 12:00 PM EDTCytomX Therapeutics (CTMX) Upgraded to Buy: Here's WhyCytomX Therapeutics (CTMX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- RTTNews · Jul 1, 11:26 AM EDTRigel Appoints Alison Hannah As CMO To Succeed Lisa Rojkjaer(RTTNews) – Rigel Pharmaceuticals, Inc. (RIGL), a commercial-stage biotechnology company, announced on Wednesday the appointment of Alison Hannah as Executive Vice President and Chief Medical Officer, succeeding Lisa Rojkjaer.
- NASDAQ.com · Jun 16, 7:59 PM EDTAfter Hours Most Active for Jun 16, 2026 : GRAB, SPCX, NVDA, INFY, BMBL, NU, SNAP, CTMX, HST, NOK, CDE, XOMThe NASDAQ 100 After Hours Indicator is up 131.97 to 29,802.92. The total After hours volume is currently 274,724,859 shares traded.The following are the most active stocks for the after hours session: Grab Holdings Limited (GRAB) is +0.0087 at $3.50, with 14,690,839 shares trad
- Zacks · Jun 4, 1:25 PM EDTREGN Expands Cancer Deal With CytomX for Bispecific TherapeuticsRegeneron expands its CytomX partnership to develop conditionally activated bispecific cancer therapies, with potential milestones nearing $4 billion.
- RTTNews · Jun 4, 9:36 AM EDTCytomX Secures $37M Regeneron Pact; Analyst Sets Price Target At $11(RTTNews) – CytomX Therapeutics Inc. (CTMX) has broadened its strategic collaboration with Regeneron Pharmaceuticals, Inc. (REGN), a move analysts view as strong validation of its PROBODY platform. The deal provides CytomX with $37 million upfront for two undisclosed targets, plu
- The Motley Fool · Jun 2, 1:45 PM EDTCytomX (CTMX) Q4 2025 Earnings Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- The Motley Fool · May 8, 2:04 PM EDTCytomX (CTMX) Q1 2026 Earnings Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- MarketBeat · May 7, 8:38 PM EDTCytomX Therapeutics Q1 Earnings Call HighlightsCytomX Therapeutics (NASDAQ:CTMX) executives highlighted progress across the company’s lead clinical programs and reviewed first-quarter 2026 financial results, emphasizing continued development momentum for its EpCAM-targeted antibody-drug conjugate Varseta-M and its masked inte
- Zacks · May 7, 7:05 PM EDTCytomX Therapeutics (CTMX) Reports Q1 Loss, Beats Revenue EstimatesCytomX Therapeutics (CTMX) delivered earnings and revenue surprises of +29.58% and +193.76%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for CytomX Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.